New York, January 26, 2026, 21:24 EST — Market closed
- ISRG was last seen at $528.81, gaining 0.96% in after-hours trading
- Company announced U.S. regulators have approved da Vinci 5 for certain cardiac procedures
- TD Cowen kicked off coverage with a Buy rating and set the price target at $660
Shares of Intuitive Surgical climbed to $528.81 on Nasdaq, marking roughly a 1% gain from the prior close. The uptick followed news that the U.S. Food and Drug Administration approved its da Vinci 5 surgical robot for select cardiac procedures. (Barchart)
The clearance arrives as investors seek new growth avenues beyond the core da Vinci system. Intuitive reported last week that global procedure volumes jumped roughly 18% in Q4. The company projects da Vinci procedure growth to slow to about 13% to 15% in 2026, down from 2025 levels. (SEC)
Cardiac is a challenging market to break into, yet it’s sizable. When hospitals launch new programs, it can boost instrument sales and eventually drive system demand — the two key factors that typically shift estimates.
Intuitive announced FDA clearance for the da Vinci 5 system in select thoracoscopically-assisted cardiac surgeries, using non-force feedback tools. This includes mitral valve repair, internal mammary artery mobilization for revascularization, plus various defect repairs and valve procedures. CEO Dave Rosa highlighted that opening the chest “can involve significant pain,” positioning the update as a step to expand minimally invasive cardiac surgery. A limited number of U.S. centers will begin working with Intuitive through 2026 to roll out da Vinci 5 cardiac programs. (GlobeNewswire)
CFO Jamie Samath reported that surgeons performed roughly 17,000 cardiac procedures globally using da Vinci systems in 2025, Becker’s ASC Review noted. The publication also highlighted Intuitive’s push for cardiac clearances on its force feedback instrument lineup. (Becker’s ASC)
Analysts added their voices too. On Monday, TD Cowen kicked off coverage of Intuitive with a Buy rating and set a $660 price target. They highlighted the da Vinci 5 product cycle and referenced a survey suggesting ongoing fleet expansion and procedure growth. (Investing)
Medtronic announced in December that the FDA had cleared its Hugo robotic-assisted surgery system for minimally invasive urologic procedures in the U.S. This marks a key step as major device makers race to challenge da Vinci’s dominance. (Medtronic News)
That said, the upside hinges on execution. Intuitive has flagged that its 2026 gross profit margin forecast assumes tariffs remain, factoring in a roughly 1.2% revenue hit from them. On top of that, it’s already bracing for slower procedure growth this year — a tough spot for a high-multiple stock if demand falters. (Reuters)
U.S. markets are closed today, so all eyes turn to Tuesday’s session for direction. The spotlight then shifts to Wednesday, when the Federal Reserve will unveil its latest decision. The FOMC statement drops at 2 p.m. EST, followed by the chair’s news conference at 2:30 p.m. EST. (Federalreserve)
